- Provide a historical overview of immune checkpoint research and examine the effect of mutational load on clinical response
- Explain how PD-1 immunotherapy stops certain cancers from turning off the anticancer immune response
- Discuss general therapeutic approaches to activating the immune system to treat cancer
- Answer your questions live during the broadcast!
James P. Allison, Ph.D.
MD Anderson Cancer Center, Houston, TX
Gordon J. Freeman, Ph.D.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Philip J. Gotwals, Ph.D
Novartis Institutes for BioMedical Research, Cambridge, MA
After you watch the webinar, check out our downloadable Application Notes and Posters on multiplex IHC to characterize immune checkpoint signaling in the tumor microenvironment.